Gregory J. Tsongalis, BS, MS, PhD
Title(s):
Professor of Pathology and Laboratory Medicine
Additional Titles/Positions/Affiliations:
Vice Chair for Research and
Director, Clinical Genomics and Advanced Technology (CGAT)
Department(s):
Pathology and Laboratory Medicine
Education:
Univ. of Massachusetts, Amherst, BS, 1984
Quinnipiac College, MHS, 1986
Univ. of Medicine and Dentistry of New Jersey, PhD 1990
Uniiv. of North Carolina, Chapel Hill, post-doctoral 1990-1994
Programs:
Norris Cotton Cancer Center
Program in Experimental and Molecular Medicine
Websites:
DHMC-CGAT.com
Contact Information:
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Office: WTRB 4th floor
Phone: 603-650-5498
Fax: 603-650-6120
Email: Gregory.J.Tsongalis@hitchcock.org
Assistant: Amber Erskine
Asst. Phone: 603-650-6821
Asst. Email: amber.j.erskine@hitchcock.org
Professional Interests:
Development of advanced diagnostic technologies and disease biomarker discovery.
Grant Information:
01/2014-12/30/15; Molecular profiling of tumor and ctDNA, riends of NCCC Scholar $50,000
03/01/13-01/31/2018; 1P20GM104416, Investigator / 2% COBRE Center for Molecular Epidemiology, Federal Direct Costs: $1,793,732
Selected Publications: |
|
Reducing dermal exposure to agrochemical carcinogens using a fluorescent dye-based intervention among subsistence farmers in rural Honduras. Evaluation of a Next-Generation Sequencing Metagenomics Assay to Detect and Quantify DNA Viruses in Plasma from Transplant Recipients. Implementation of Reverse Transcriptase PCR Testing for Severe Acute Respiratory Syndrome Coronavirus 2 under the US Food and Drug Administration Emergency Use Authorization. Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer. HPV, vaccines, and cervical cancer in a low- and middle-income country. Clinical Validation of a 106-SNV MALDI-ToF MS Pharmacogenomic Panel. Implementation of an Emergency Use Authorization Test During an Impending National Crisis. Rapid EGFR mutation testing in lung cancer tissue samples using a fully automated system and single-use cartridge. |
|
